【摘要】：目的:考察陳皮及其主要活性成分對(duì)脾虛模型大鼠血清胃泌素(GAS)、血漿乙酰膽堿(ACh)、P物質(zhì)(SP)、胃動(dòng)素(MTL)和血管活性腸肽(VIP)的影響。方法:以苦寒瀉下加饑飽失常法復(fù)制大鼠脾虛模型,陳皮水煎液、橙皮苷、辛弗林及4個(gè)單體組合物(橙皮苷、辛弗林、川陳皮素、橘皮素)分別灌胃給藥,采用ELISA法檢測(cè)血清GAS、血漿ACh、SP、MTL和VIP的含量變化,考察陳皮水煎液及其主要活性成分對(duì)脾虛模型大鼠的影響。結(jié)果:模型組大鼠ACh、GAS、MTL和SP含量較空白對(duì)照組明顯降低,而VIP含量則顯著增加。給藥后,嗎丁啉6 mg/kg組GAS和MTL水平較模型組顯著升高;橙皮苷12.68 mg/kg劑量組血清中GAS含量與模型組比較顯著增加;橙皮苷12.68、25.36 mg/kg劑量組血漿中ACh含量,6.34 mg/kg劑量組血漿中SP含量,6.34、12.68、25.36 mg/kg劑量組血漿中MTL含量以及6.34 mg/kg劑量組血漿中VIP含量較模型組明顯降低。辛弗林8.4 mg/kg劑量組血漿中ACh和MTL水平較模型組顯著增加;辛弗林2.1 mg/kg劑量組血漿中SP含量和8.4 mg/kg劑量組血漿中VIP含量與模型組比較明顯降低。4個(gè)單體組合物46.36 mg/kg劑量組血清中GAS、血漿中ACh以及SP含量較模型組比較顯著增加;4個(gè)單體組合物11.59mg/kg劑量組血清中GAS、血漿中ACh、SP含量以及四個(gè)單體組合物11.59、23.18、46.36 mg/kg劑量組血漿中MTL含量與模型組比較明顯降低。陳皮水煎液1.05 g/kg劑量組血清中GAS含量,4.2 g/kg劑量組血漿中ACh和SP含量與模型組比較明顯增加;陳皮水煎液1.05、2.1 g/kg劑量組血漿中MTL和VIP含量較模型組明顯降低。結(jié)論:橙皮苷和辛弗林是陳皮的藥效物質(zhì)。橙皮苷可能通過(guò)升高GAS的含量和抑制ACh、SP、MTL和VIP的分泌來(lái)促胃腸運(yùn)動(dòng);辛弗林可能通過(guò)增加ACh和MTL的分泌和降低SP和VIP的含量來(lái)促胃腸運(yùn)動(dòng);陳皮可能通過(guò)升高ACh、GAS和SP的含量和抑制MTL和VIP的分泌來(lái)促胃腸運(yùn)動(dòng),這可能是陳皮促胃腸動(dòng)力的機(jī)制之一。
[Abstract]:Aim: to investigate the effects of pericarp and its main active components on serum gastrin (GAS), plasma acetylcholine (ACh) motilin (SP),) motilin (MTL) and vasoactive intestinal peptide (VIP) (VIP) in rats with spleen deficiency. Methods: the spleen asthenia model of rats was induced by cold diarrhea and hunger and satiety. The decoction of pericarp, hesperidin, Simverin and four monomers (hesperidin, Simverin, Chuan Chen Pei, Orange Peel) were administered intragastrically respectively. The changes of plasma ACh,SP,MTL and VIP in serum GAS, were detected by ELISA method, and the effects of the decoction and its main active components on the spleen deficiency model rats were investigated. Results: the content of ACh,GAS,MTL and SP in the model group was significantly lower than that in the control group, while the content of VIP in the model group was significantly higher than that in the control group. After administration, the levels of GAS and MTL in morpholine 6 mg/kg group were significantly higher than those in model group, and the serum GAS content in hesperidin 12.68 mg/kg group was significantly higher than that in model group. Content of ACh in plasma of the dose group of 12. 68 ~ 25. 36 mg/kg the content of SP in the plasma of the 6. 34 mg/kg group was significantly lower than that of the model group. The content of MTL in the plasma of the dose group of 6. 34 mg/kg and the content of VIP in the plasma of the dose of 6. 34 mg/kg were significantly lower than that of the model group. The levels of plasma ACh and MTL in the Simferine 8.4 mg/kg group were significantly higher than those in the model group. Compared with model group, the plasma SP content of Simferine 2.1 mg/kg dose group and the plasma VIP content of 8.4 mg/kg dose group were significantly lower than those of model group. The ACh and SP contents in serum of four monomer compositions of 46.36 mg/kg group were significantly higher than those of model group. The content of ACh,SP in serum of the four monomeric compositions (11.59mg/kg) and of the four monomer compositions (11.59 ~ 23.186.36 mg/kg) was significantly lower than that of the model group (P < 0.05), and the content of ACh,SP in the plasma of the four monomeric compositions was significantly lower than that of the model group. The contents of serum GAS and SP in serum of the group of 1.05 g/kg decoction and 4.2 g/kg were significantly higher than those of the model group, and the contents of MTL and VIP in the group of 1.05 ~ 2.1 g/kg were significantly lower than those in the model group. Conclusion: hesperidin and Simverin are the effective substances of pericarp. Hesperidin may promote gastrointestinal motility by increasing the content of GAS and inhibiting the secretion of ACh,SP,MTL and VIP, Simverin may promote gastrointestinal motility by increasing the secretion of ACh and MTL and decreasing the contents of SP and VIP. Pericarp may promote gastrointestinal motility by increasing the content of ACh,GAS and SP and inhibiting the secretion of MTL and VIP, which may be one of the mechanisms of promoting gastrointestinal motility.
【作者單位】： 江西中醫(yī)藥大學(xué)現(xiàn)代中藥制劑教育部重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家自然科學(xué)基金項(xiàng)目(81460575,81260612) 江西中醫(yī)藥大學(xué)校級(jí)研究生創(chuàng)新項(xiàng)目(JZYC15S43)
【分類(lèi)號(hào)】：R285.5;R-332

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李玉娥;謝東;羅璇;位蘭;彭克美;;血管活性腸肽與臨床疾病[J];養(yǎng)殖與飼料;2005年11期

2 張e，

本文編號(hào)：2224711